BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 02, 2015
 |  BioCentury  |  Emerging Company Profile

Exosomes for AD

NanoSomiX developing blood-based diagnostic of validated AD markers

NanoSomiX Inc. is developing a blood-based diagnostic that measures well-studied biomarkers of Alzheimer's disease as a cheaper and less invasive method to diagnose AD than spinal taps or brain imaging. The diagnostic also could be used to identify patients who are not yet symptomatic and to perform differential diagnoses.

NanoSomiX's diagnostic measures biomarkers in neural-derived exosomes, which can cross the blood-brain barrier. Exosomes are small vesicles shed by mammalian cells that contain non-degraded proteins and RNA specific to their cellular origin.

According to President and CEO John Osth, fellow co-founder Edward Goetzl was the first to identify a signature to detect neural-derived exosomes in blood. Goetzl is principal scientist at NanoSomiX, which then developed an undisclosed method to isolate the exosomes and measure the levels of four proteins using ELISA assays.

The proteins are beta amyloid 42; microtubule-associated protein tau (tau; MAPT; FTDP-17); and two different forms of phosphorylated tau (p-tau).

"We have markers that are highly respected and studied but could never before be...

Read the full 861 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >